April 13, 2024

Infectious Disease Therapeutics Market Trends: Innovations in Infectious Disease Management

Infectious Disease Therapeutics Market

Infectious diseases have always posed significant threat to public health. The continuous emergence and re-emergence of various infections have placed additional burden on healthcare systems worldwide. Infectious disease therapeutics provide treatment to conditions caused by pathogenic microorganisms such as bacteria, viruses, parasites or fungi. Some of the key products in this market include anti-bacterial drugs for treating bacterial infections, anti-viral drugs for viral infections, anti-fungal medicines for fungal infections and anti-parasitic drugs for parasitic infections. The growing prevalence of infectious illnesses and rising demand for effective treatments to manage infectious disease outbreaks is fueling the demand for infectious disease therapeutics.

The global Infectious Disease Therapeutics Market is estimated to be valued at US$ 170.67 Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The demand for new drugs and vaccines to fight antimicrobial resistance is a significant trend in infectious disease therapeutics market. The emergence and spread of drug-resistant strains has reduced the effectiveness of existing treatments. This has prompted pharmaceutical companies to invest heavily in research and development of novel therapies. For instance, GSK is developing vaccines for staphylococcus aureus and salmonella – two bacteria that have developed resistance to multiple antimicrobial drugs. Development of rapid diagnostic tests to enable early detection and targeted treatment is another key trend shaping the market. Companies are introducing innovative point-of-care diagnostic kits that can identify pathogens in a short duration aiding fast clinical decision making.

Porter’s Analysis

Threat of new entrants: The threat is moderate for the infectious disease therapeutics market as the R&D and clinical trials require huge investment. However, new molecules for drug resistant infections offer opportunities.

Bargaining power of buyers: The bargaining power is moderate as the demand is inelastic in nature given infectious diseases have life threatening impact. However, presence of generic alternatives provide options.

Bargaining power of suppliers: The bargaining power of suppliers is high given the specialized nature of raw materials and skills required. Suppliers can influence prices.

Threat of new substitutes: The threat is low as new drug molecules take significant time and investment given stringent regulatory processes for approval.

Competitive rivalry: The rivalry is high among existing players given large market size and opportunities. Players compete on drug pricing, portfolio expansion and marketing.

Key Takeaways
The global infectious disease therapeutics market is expected to witness high growth over the forecast period driven byrising prevalence of infectious diseases, growing R&D and increasing healthcare expenditure. The global Infectious Disease Therapeutics Market is estimated to be valued at US$ 170.67 Bn in 2023 and is expected to exhibit a CAGR of 3.7% over the forecast period 2023 to 2030.

Regional analysis: North America dominated the market in 2020 due to presence of majority of leading players, growing R&D activities and increasing healthcare spending.However, Asia Pacific is expected to grow at the fastest pace during the forecast period aided by rising patient pool, increasing healthcare investments and growing awareness.

Key players: Key players operating in the infectious disease therapeutics market are Novartis International AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceutical, F. Hoffmann-La Roche AG, BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH. Players focus on expanding their product portfolios and accelerating new drug development efforts to effectively address the unmet needs.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it